The approved ANDA is therapeutically equivalent to GlaxoSmithKline LLC's Lamictal XR extended-release tablets in strength of ...

The stock hits an intraday high on Thursday, October 3, 2024, after getting approval from USFDA for general medication drug.

Patients with metastatic castration-sensitive prostate cancer are recommended to be treated with enzalutamide tablets.

Zydus Lifesciences receives USFDA approval to manufacture Enzalutamide tablets, a generic prostate cancer treatment drug, for ...

Zydus Lifesciences share price will remain in focus on October 3 after the company received tentative approval from the ...

Pharma stock engaged in manufacturing and distributing of pharmaceutical products gained traction on Thursday’s trading ...

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate ...

This approval adds to Alembic Pharma's growing portfolio, which now includes 216 ANDA approvals from the USFDA, comprising ...

Share Market Updates - Find here all the updates related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets ...

Alembic has a cumulative total of 216 ANDA approvals (188 final approvals and 28 tentative approvals) from USFDA.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Lamotrigine Extended-Release Tablets USP, 200 mg, 250 ...

The clearance from the US FDA opens the doors for Shivalik Rasayan to file new products for the facility, aimed at exporting ...